BX Swiss TOP 30 CHF

BX Swiss TOP 30 CHF handeln
1.372,35 PKT -16,20 PKT -1,17 %
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

WKN SL0CLV

ISIN DE000SL0CLV3


Analysen zu BX Swiss TOP 30 CHF-Werten

Datum Rating Analyst
04.02.19 UBS buy Deutsche Bank AG
04.02.19 Roche Reduce HSBC
04.02.19 Holcim Hold HSBC
04.02.19 Novartis Hold Deutsche Bank AG
01.02.19 Roche Reduce HSBC
01.02.19 Zurich Insurance Neutral UBS AG
01.02.19 Swiss Re Sell UBS AG
01.02.19 Givaudan Sell Goldman Sachs Group Inc.
01.02.19 Novartis Underweight Barclays Capital
01.02.19 Roche Neutral Credit Suisse Group
01.02.19 Novartis Underweight JP Morgan Chase & Co.
31.01.19 Roche Neutral UBS AG
31.01.19 Roche Hold Deutsche Bank AG
31.01.19 Novartis Neutral Credit Suisse Group
31.01.19 Novartis Underweight JP Morgan Chase & Co.
31.01.19 Roche overweight JP Morgan Chase & Co.
31.01.19 Novartis Conviction Buy List Goldman Sachs Group Inc.
31.01.19 Roche buy Jefferies & Company Inc.
30.01.19 Novartis Hold Deutsche Bank AG
30.01.19 Nestlé overweight JP Morgan Chase & Co.
30.01.19 Roche buy Goldman Sachs Group Inc.
30.01.19 Novartis Neutral UBS AG
30.01.19 Novartis buy Kepler Cheuvreux
30.01.19 Roche Neutral UBS AG
30.01.19 Zurich Insurance Hold Jefferies & Company Inc.
30.01.19 Novartis buy Jefferies & Company Inc.
30.01.19 Nestlé buy Goldman Sachs Group Inc.
29.01.19 Swiss Re Outperform Credit Suisse Group
29.01.19 Zurich Insurance Outperform Credit Suisse Group
29.01.19 Novartis Underweight JP Morgan Chase & Co.
29.01.19 Zurich Insurance Neutral JP Morgan Chase & Co.
29.01.19 Givaudan Hold Deutsche Bank AG
29.01.19 Roche overweight Barclays Capital
29.01.19 UBS buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
28.01.19 Roche Neutral Credit Suisse Group
28.01.19 Nestlé buy Jefferies & Company Inc.
28.01.19 Holcim Sell UBS AG
28.01.19 Swiss Re overweight JP Morgan Chase & Co.
28.01.19 UBS overweight JP Morgan Chase & Co.
28.01.19 UBS overweight JP Morgan Chase & Co.